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============

A study of patients with stable angina and moderate left ventricular systolic dysfunction has shown that the addition of ivabradine to bisoprolol produced additional anti-anginal and anti-ischaemic effects that were not achieved with up-titration of bisoprolol.[@R01] This indicative study is of importance to clinicians as they are frequently faced with patients on β-blockers who are not able to tolerate the full target dose, as defined from evidencebased clinical trials.

Ivabradine is a novel agent that reduces heart rate (HR) by selective and specific inhibition of the If current in sino-atrial cells, leading to prolongation of the slow diastolic depolarisation phase of the action potential.

Placebo-controlled studies in angina patients have shown that ivabradine improves exercise tolerance, lengthens time to ischaemia, and has anti-anginal and anti-ischaemic efficacy similar to that of atenolol or amlodipine. The ASSOCIATE study in stable angina patients receiving the beta-blocker atenolol has demonstrated that ivabradine reduces HR and improves exercise capacity ([Fig. 1](#F1){ref-type="fig"}).
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This study, presented at the ACC congress, included 29 patients with chronic stable angina (class II) who had had a myocardial infarction more than three months before and had moderate left ventricular systolic dysfunction on stable therapy, including bisoprolol 5 mg once daily. Therapy included aspirin, and statins enalapril and furosemide in cases with congestive heart failure.

Over a period of two months, resting heart rate was reduced in both groups to similar levels (60 bpm). However more patients in the ivabradine-treated group (7.5 mg twice daily) showed improvements in angina and more patients moved from angina class II to angina class I than those who received the up-titrated bisoprolol dose (10 mg once daily). Importantly, walking distance and exercise tolerance improved in the ivabradine group while no improvement occurred in the bisoprolol-treated group.
